The Parkinson’s Disease Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.
DelveInsight's Parkinson’s Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson’s Disease emerging drugs, Parkinson’s Disease market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
Key highlights of the Parkinson’s Disease Market Research Report
- According to DelveInsight’s analysis, it has been observed that Primary Parkinsonism or Idiopathic Parkinson’s cases are more prominent in comparison to Secondary or atypical parkinsonism.
- According to DelveInsight’s analysis, males are more prominent for developing PD in comparison to female.
- The total diagnosed prevalent population of Parkinson’s disease in the 7MM expected to rise to 3,284,084 in 2030, during the study period [2018–2030]. Estimates show the highest diagnosed prevalent population of Parkinson’s disease is in the United States followed by Japan.
- Leading Parkinson’s Disease Companies such as Newron Pharmaceuticals, Kyowa Kirin, AbbVie, Acadia Pharmaceuticals, Inc., Acorda Therapeutics Inc, Hisamitsu Pharmaceutical Co. Inc., Sunovion Pharmaceuticals, Adamas Pharmaceuticals, Neurocrine Biosciences, Adamas Pharmaceutical, Teva Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Pharma Two B, Mitsubishi Tanabe Pharma, Addex Pharma S.A., Ipsen, Annovis Bio Inc., and several others
- The Promising Parkinson’s Disease Therapies in the pipeline include tradefylline (KW-6002), Opicapone, Gocovri, Xadago, Osmolex ER, Duopa (Duodopa, ABT-SLV187), and several others
Know which therapies are expected to grab major Parkinson’s Disease Market Share @ Parkinson’s Disease Market Research Report
Parkinson’s Disease Overview
Parkinson’s disease is a type of movement disorder that can affect the ability to perform common, daily activities. The most common motor symptoms of PD are tremor (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia).
Parkinson’s Disease Epidemiology Segmentation in the 7MM
- Total Parkinson’s Disease Prevalent cases
- Parkinson’s Disease Gender-specific cases
- Parkinson’s Disease Age-specific cases of
- Parkinson’s Disease Prevalent population based on the onset,
- Parkinson’s Disease Stage-specific cases
For further information of this report to understand which factors are driving Parkinson’s Disease epidemiology trends @ Parkinson’s Disease Epidemiological Insights
Parkinson’s Disease Treatment Market
The present Parkinson’s Disease treatment options include medication, surgery, and complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that includes Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine. The treatment is given based on the stages of the disease, symptoms shown, and those who are already receiving some medication. Based on the mentioned criteria the treatment can be classified into early-stage, late-stage, and nonmotor symptoms.
Parkinson’s Disease Market Insights
At present, different class of therapies are prescribed of the treatment of Parkinson disease. Levodopa is the most preferred therapy for the treatment of Parkinson disease and its symptoms, followed by dopamine agonist. These therapies are prescribed either mono or in combination with the other class of therapies
Parkinson’s Disease Companies
- Newron Pharmaceuticals
- Kyowa Kirin
- AbbVie
- Acadia Pharmaceuticals, Inc.
- Acorda Therapeutics Inc
- Hisamitsu Pharmaceutical Co. Inc.
- Sunovion Pharmaceuticals
- Adamas Pharmaceuticals
- Neurocrine Biosciences
- Adamas Pharmaceutical
- Teva Pharmaceuticals
- Amneal Pharmaceuticals
- Cerevel Therapeutics
- Pharma Two B
- Mitsubishi Tanabe Pharma
- Amneal Pharmaceuticals
- Addex Pharma S.A.
- Ipsen
- Annovis Bio Inc., and several others
Parkinson’s Disease Drugs
- Istradefylline (KW-6002)
- Opicapone
- Gocovri
- Xadago
- Osmolex ER
- Duopa (Duodopa, ABT-SLV187), and several others
Learn more about the Parkinson’s Disease therapies in clinical trials @ Drugs for Parkinson’s Disease Treatment
Parkinson’s Disease Market Forecast
For patients with advanced Parkinson’s disease, mostly surgeries are preferred. Most of the treatments are aimed at helping the tremor or rigidity that comes with the disease. In some patients, surgery may decrease the amount of medication that is needed to control the symptoms. There are three types of surgeries that may be performed for Parkinson’s disease, including the following: Lesion surgery (burning of tissue), deep brain stimulation (DBS), and neural grafting or tissue transplants. Deep brain stimulation was approved in 2002 as adjunctive therapy in reducing motor fluctuation in advanced Parkinson disease. In this type of surgery, a small electrode is placed in the critical parts of the brain that help to control movement.
Scope of the Parkinson’s Disease Market Forecast Report
- Coverage- 7MM
- Study Period- 2019-2032
- Forecast Period-2022-2032
- Parkinson’s Disease Companies- Newron Pharmaceuticals, Kyowa Kirin, AbbVie, Acadia Pharmaceuticals, Inc., Acorda Therapeutics Inc, Hisamitsu Pharmaceutical Co. Inc., Sunovion Pharmaceuticals, Adamas Pharmaceuticals, Neurocrine Biosciences, Adamas Pharmaceutical, Teva Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Pharma Two B, Mitsubishi Tanabe Pharma, Addex Pharma S.A., Ipsen, Annovis Bio Inc., and several others
- Parkinson’s Disease Therapies- tradefylline (KW-6002), Opicapone, Gocovri, Xadago, Osmolex ER, Duopa (Duodopa, ABT-SLV187),
- Chronic Gout Therapeutic Assessment- Current marketed and emerging therapies
- Parkinson’s Disease Market Dynamics- Parkinson’s Disease Market Drivers and Barriers
- Competitive Intelligence Analysis- SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Parkinson’s Disease Market Access and Reimbursement
Discover more about Parkinson’s Disease medications in development @ Parkinson’s Disease Clinical Trials
Table of Content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Parkinson’s Disease Market Treatment
- Parkinson’s Disease Marketed Products
- Parkinson’s Disease Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Parkinson’s Disease Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Parkinson’s Disease Market Drivers
- Parkinson’s Disease Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business Executive @ Parkinson’s Disease Market Size
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
